Coronary artery calcification in patients with advanced chronic kidney disease

Xiadan Xiang¹, Ji He², Wei Zhang², Qiang He* and Yueming Liu*²

Abstract

Introduction Cardiovascular disease (CVD) is associated with higher morbidity and mortality rates in patients with chronic kidney disease (CKD). Studies have shown that vascular calcification is a major predictor of CVD. Vascular calcification in the CKD population is associated with various risk factors, and changes in bone and mineral metabolism have been linked to an increased risk of atherosclerosis. Therefore, we aimed to investigate the correlation between vascular calcification and bone metabolism, which is necessary to improve the survival and prognosis of patients with CKD.

Methods We included 146 patients with CKD who received coronary artery calcification (CAC) scores at our hospital from May 2017 to November 2018. Spearman rank correlation analysis, Mann–Whitney U test, and Kaplan–Meier method were used to analyze laboratory data and all-cause mortality.

Results In the 146 patients, chronic glomerulonephritis accounted for the most common cause of CKD, at approximately 39.0%. Spearman rank correlation analysis on the factors influencing vascular calcification in patients with CKD showed that CAC score was significantly and positively correlated with C-reactive protein, N-terminal/midregion osteocalcin (N-MID), N-terminal peptide of type 1 procollagen (P1NP), β-cross-linked C-telopeptide of type 1 collagen (β-CTx), and parathyroid hormone (P = 0.0423, P = 0.0432, P = 0.0235, P = 0.0061, P < 0.0001, respectively). Serum calcium levels were positively correlated with N-MID, P1NP, β-CTx, and iPTH (r = 0.19, r = 0.24, r = 0.21, r = 0.21, respectively), and serum phosphorus levels were positively correlated with N-MID, P1NP, β-CTx, and iPTH (r = 0.50, r = 0.37, r = 0.50, r = 0.55, respectively). However, no difference was found in CVC scores among patients with CKD in different stages and receiving different treatments. In the Kaplan–Meier analysis of all-cause hospitalization and mortality rates, patients with CAC > 400 had a higher risk.

Conclusion We found that the primary cause of CKD is glomerulonephritis, and the CAC score is positively correlated with inflammatory and bone metabolism markers, with a higher risk of all-cause mortality and cardiovascular hospitalization when the CAC score is greater than 400.

Keywords Chronic kidney disease, Glomerulonephritis, Vascular calcification

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Chronic kidney disease (CKD) is a major public health concern worldwide [1]. The overall prevalence of CKD in China is approximately 10.8%, affecting an estimated population of 120 million [2]. Patients with CKD or end-stage renal disease have a significantly higher incidence and mortality of cardiovascular disease (CVD) than the general population [3]. Vascular calcification is a pathological process characterized by the accumulation of mineral deposits on arterial walls and is considered a major predictor of CVD development [4]. It is a common complication in patients with CKD, which often occurs alongside a multitude of adverse cardiac events, including arrhythmias, ischemic damage, myocardial infarction, and sudden cardiac death [5]. Early diagnosis and intervention for vascular calcification may prevent the progression of CVD in patients with CKD.

The pathological mechanisms of vascular calcification in the population with CKD are complex and involve traditional risk factors, including sex, age, smoking history, hypertension, diabetes, and hyperlipidemia, as well as risk factors unique to patients with CKD, such as kidney function decline, elevated parathyroid hormone (PTH) level, inflammation, oxidative stress, and mineral and bone disorders [6]. In CKD, a cell-mediated process driven by alterations in vascular smooth muscle cells called tunica media vascular calcification is a characteristic manifestation of EVA [7, 8]. The milieu created by uremic toxins and other factors that induce cellular oxidative stress is key to VSMCs calcification[9–11]. Hypercalcemia and hyperphosphatemia will disrupt the inhibitory defense system in CKD, while hyperparathyroidism and hypomagnesemia have the potential to be further aggravated [9, 12]. Imbalanced signal transmission if not promptly adjusted, activation of the necessary osteogenic / chondrogenic transcription factors in the context of high calcium and phosphate will further induce VSMC osteogenic / chondrogenic protein expression. Ultimately, uremic VSMCs undergo osteochondrogenic differentiation and vascular ossification[13–16]). Previous evidence revealed that hyperphosphatemia and hypercalcemia are associated with increased cardiovascular mortality in patients with CKD [17]. Additionally, a meta-analysis consisting of 25 studies and 10,299 patients suggested that patients with altered bone and mineral metabolism should be screened for the risk of atherosclerotic vascular abnormalities [18]. ( the literature prevalence of CACs at the moment of transplantation between 35% and 70% is reported[19, 20]; According to reports by Alfier [21]et al the presence of CACs at T0 and the age were the only independent factors in determining the CAC progression )Therefore, a better understanding of the correlation between vascular calcification and bone metabolism may contribute to the development of novel management strategies for mineral and bone disorders, thereby improving the survival and prognosis of patients with CKD.

In the current study, we aimed to investigate the correlation between coronary artery calcification (CAC) score and bone metabolism indices in patients with CKD. The clinical outcomes after the CAC test were also evaluated. Our results showed that patients with CKD with a high risk of vascular calcification also showed an increased rate of all-cause and cardiovascular hospitalizations.

Materials and methods
Subjects
A total of 146 patients diagnosed with CKD, who underwent CAC scoring at our hospital between May 2017 and November 2018, were recruited for this study. The diagnosis and staging of CKD were based on the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the evaluation and management of chronic kidney disease. CKD is defined as kidney damage or an estimated glomerular filtration rate (eGFR) of <60 ml/min/1.73 m² for more than 3 months. eGFR was calculated according to diet modification in renal disease study equation: eGFR=186 × (serum creatinine)−1.154 × (age)−0.203 × (0.742, if female). Patients with severe liver diseases, malignant tumors, or acute inflammatory diseases were excluded.

CAC was determined using spiral computed tomography (CT) as previously described [22]. CT was performed by an experienced radiologist using a 640-slice CT scanner (Toshiba, Tokyo, Japan). CAC was scored according to the Agatston scoring method provided by the KDIGO, in which the lesion score was calculated by multiplying the lesion area (mm²) by a density factor [23]. Weighted density scores were graded as follows: 130–199 HU: 1, 200–299 HU: 2, 300–399 HU: 3, and ≥400 HU: 4. The total CAC score was calculated by summing the scores for all lesions. A score of 0 was defined as no risk of cardiovascular events or mortality; 1–100, low risk; 101–400, intermediate risk; and >400, high risk [24].

Clinical and demographic data collection
The clinical and demographic profiles of all patients were collected. Fasting blood samples were collected from all subjects for the detection of hemoglobin (HGB), C-reactive protein (CRP), albumin (ALB), creatinine, blood urea nitrogen, calcium (Ca), phosphorus (P), fasting blood glucose (FBG), PTH, 25 hydroxyvitamin D (25(OH)D), N-terminal peptide of type 1 procollagen (P1NP), β-cross-linked C-telopeptide of type 1 collagen (β-CTX), and N-terminal/midregion osteocalcin (N-MID) using AU5821 Clinical Chemistry Analyzer (Beckman Coulter, Inc., Brea, USA), XE-2100 Hematology Analyzer (Sysmex, Kobe, Japan), and Cobas E601
Immunology Analyzer (Roche, Basel, Switzerland). When the serum ALB level was less than 40 g/L, the measured serum Ca was corrected for ALB concentration (g/L) as follows: corrected Ca (mmol/L) = measured Ca (mmol/L)/0.02×(40-ALB concentration). The IE33 echocardiography system (Philips, Amsterdam, Netherlands) was used to measure the indicators of cardiac structure and function, including the left atrial diameter, right atrial diameter, left ventricular (LV) diameter, right ventricular diameter, and LV ejection fraction.

Hospitalization and survival analysis
The hospitalization and mortality rates of the patients between the administration of the CAC test and the day of data collection (or death) were recorded. One patient was lost to follow-up after CAC testing. Echocardiographic results from three patients were missing. Therefore, a total of 146 patients were included in the analysis. All-cause mortality rate was defined as the percentage of deaths among the 146 patients. Major adverse cardiovascular events (a single or composite endpoint of myocardial infarction, stroke, heart failure, or cardiovascular death) were also recorded [25].

Statistical analysis
The program R3.01 was used for data analysis and plotting of graphs. Quantitative variables with non-normal distributions are expressed as medians (Q1, Q3) and analyzed using Spearman's rank correlation analysis. Qualitative data are summarized as percentages (%). The Mann–Whitney U test was used to compare statistical significance among groups. The Kaplan–Meier method was used for survival analysis. Statistical significance was set at P<0.05.

Results
Clinical and demographic characteristics of patients with CKD
A total of 146 patients with CKD with a mean age of 60.49±16.39 years were included in the analysis. The patients comprised 92 men (63%) and 54 women (37%). The most common causes of CKD identified in this population were chronic glomerulonephritis (57, 39.0%), diabetic nephropathy (41, 28.1%), and hypertensive nephropathy (34, 23.3%). The etiologies of CKD in the remaining 14 patients (9.6%) were kidney obstruction and drugs toxic to the kidney (Table 1). The median levels of HGB, CRP, and ALB in these patients were 96.5 (84.75, 109.25) g/L, 7.80 (1.30, 25.18) mg/L, and 34.04±4.96 g/L, respectively. According to the Clinical Practice Guidelines for Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) provided by the KDIGO [26], 37.35%, 44.58%, and 78.31% of the patients showed abnormalities in Ca, P, and PTH levels, respectively. The echocardiographic results showed that the median left atrial diameter, right atrial diameter, and LV ejection fraction were 39 (35, 43) mm, 22 (20, 23) mm, and 63 (57, 67) %, respectively.

Vascular calcification in patients with CKD
The median CAC score in 146 patients with CKD was 216 (1.00, 909.75) (Table 1). Thirty-five (23.97%) patients had a CAC score of 0. Twenty-six (17.81%) patients were categorized into the low-risk group, with a score of 1–100. Twenty-nine (19.86) patients were in the intermediate-risk group, with a score of 101–400. Fifty-six (38.36%) patients had a CAC score >400 (high-risk group). In total, 85 patients had a CAC score >100, indicating that the prevalence of vascular calcification in the study participants was 58.22%.

Factors influencing vascular calcification in patients with CKD
Spearman's rank correlation analysis was performed to identify the factors influencing vascular calcification in these patients. The results showed that CAC score was not correlated with age, Ca, P, 25(OH)D, or LV ejection fraction (P=0.1028, P=0.4299, P=0.7441, P=0.1232, P=0.6446, respectively). In addition, no significant correlations were detected in CAC score and HGB, ALB, creatinine, blood urea nitrogen, and FBG levels (data not shown). However, CAC score was significantly and positively correlated with CRP, N-MID, P1NP, β-CTx, and PTH levels (r=0.0423, r=0.14; r=0.0432, r=0.16; r=0.0235, r=0.19; r=0.0061, r=0.23; P<0.0001, r=0.35, respectively). Serum Ca level was positively and significantly correlated with N-MID, P1NP, β-CTx, and iPTH levels (r=0.19, r=0.24; r=0.19, r=0.21, respectively), and serum P level was positively correlated with N-MID, P1NP, β-CTx, and iPTH (r=0.50, r=0.37, r=0.50, r=0.55, respectively) with statistical significance (Fig. 1).

Vascular calcification in patients with CKD at different stages
Patients with CKD were categorized into the following groups based on their eGFR: CKD stage 3, CKD stage 4, CKD stage 5 (without dialysis), CKD stage 5 (hemodialysis), and CKD stage 5 (peritoneal dialysis). There were 2 (1.4%), 4 (2.7%), 20 (13.7%), 83 (56.8%), and 37 (25.3%) patients in the above-mentioned groups with CAC scores of 305 (225, 385), 244 (23.25, 539.25), 182 (51, 909.25), 225 (1, 900), and 224 (0, 1328), respectively (Table 2; Fig. 2). No significant difference was found in the CAC scores among these groups (P=0.985).

Hospitalization and survival analysis
The hospitalization and mortality rates of the patients between the administration of the CAC test and the
day of data collection (or death) were recorded. The median duration was 308 days (range 34–605). During this period, 27 patients were hospitalized because of cardiovascular events. Ten patients died, with an all-cause mortality rate of 6.58% and a cardiovascular mortality rate of 4.11%. After dividing the participants into different groups according to CAC scores (no risk, low risk, intermediate risk, and high risk), we constructed Kaplan–Meier survival curves for each group using all-cause hospitalization, cardiovascular hospitalization, or death as the endpoint of interest. Patients with CAC scores of >400 (high-risk group) had a significantly higher risk of all-cause (Fig. 3) and cardiovascular (Fig. 4) hospitalizations than patients with scores ≤400 (P<0.0001). However, no statistically significant difference was found in the survival of patients with CKD with different CAC scores (P=0.28) (Fig. 5). COX regression analysis was performed separately for all-cause hospitalization, cardiovascular hospitalization, and mortality outcomes, and CAC>101 was found to be an independent risk factor in all-cause hospitalization (Table 3); it was independently

| Table 1 | Baseline characteristics |
|---------|-------------------------|
| Overall (n = 146) | |
| **Age (yr, mean ± SD)** | 60.49 ± 16.39 |
| **Sex, n (%)** | |
| male | 92 (63.0%) |
| female | 54 (37.0%) |
| **Primary renal disease, n (%)** | |
| CGN | 57 (39.0%) |
| DN | 41 (28.1%) |
| HTN | 34 (23.3%) |
| Others | 14 (9.6%) |
| **RRT, n (%)** | |
| HD | 83 (56.8%) |
| PD | 37 (25.3%) |
| no | 26 (17.8%) |

**Laboratory analysis**

| | |
|---|---|
| HGB | 96.5 (84.75, 109.25) |
| CRP | 7.80 (1.30, 25.18) |
| ALB | 34.04 ± 4.96 |
| Ca | 2.35 ± 0.22 |
| P | 1.68 (1.26, 2.27) |

**Bone metabolic markers**

| | |
|---|---|
| iPTH | 284.35 (108.55, 983.73) |
| βCTx | 1861.50 (1133.25, 4610.75) |
| N-MID | 176.85 (59.90, 275.03) |
| 25(OH)D | 13.80 (7.55, 22.52) |
| P1NP | 239.90 (139.53, 1200.00) |

**Cardiac ultrasound**

| | |
|---|---|
| LA (mm) | 38.91 ± 6.32 |
| RV (mm) | 22.00 (20.00, 23.00) |
| EF (%) | 63 (57, 67) |

**Calcification score M(Q1,Q3)**

| | |
|---|---|
| 0 | 35 (23.97%) |
| 1–100 | 26 (17.81%) |
| 101–400 | 29 (19.89%) |
| >400 | 56 (38.36%) |

*CGN: Chronic glomerulonephritis; DN: Diabetic nephropathy; HTN: Hypertensive nephropathy; HD: Hemodialysis; PD: Peritoneal dialysis; iPTH: parathyroid hormone; βCTx: β cross-linked C telopeptide of type 1 collagen; N-MID: N-MID osteocalcin; 25(OH)D: 25 hydroxyl-vitamin D; P1NP: N-terminal peptide of type 1 procollagen; PTH: parathyroid hormone; AO: aorta diameter; β-CTx: β cross-linked C-telopeptide of type 1 collagen; EF (%), left ventricular ejection fraction."

**Fig. 1** Factors influencing vascular calcification in CKD patients

(Spearman rank correlation analysis was performed to identify the factors influencing vascular calcification in CKD patients. * indicates statistical significance. * P<0.05, ** P<0.01, *** P<0.001. CRP, c-reactive protein; Ca, calcium; P, phosphorus; N-MID, N-MID osteocalcin, 25(OH)D, 25 hydroxyl-vitamin D; P1NP, N-terminal peptide of type 1 procollagen; PTH, parathyroid hormone; AO, aorta diameter; β-CTx, β cross-linked C-telopeptide of type 1 collagen; EF (%), left ventricular ejection fraction.)

| Table 2 | Prevalence of vascular calcification in CKD patients at different stages |
|---------|-------------------------|
| **CKD stage** | **Cases n (%)** | **CAC score M(Q1,Q3)** |
| 3 | 2 (1.4%) | 305 (225, 385) |
| 4 | 4 (2.7%) | 244 (23.25, 539.25) |
| 5* | 20 (13.7%) | 182 (51, 909.25) |
| -HD | 83 (56.8%) | 225 (1, 900) |
| -PD | 37 (25.3%) | 224 (0, 1328) |

*No dialysis treatment
associated with Age, ALB, and Urea in patients who died (Table 4); and CAC>101 was a significant independent risk factor in patients with cardiovascular hospitalization (Table 5).

Discussion
Vascular calcification is associated with significantly poor prognosis and mortality in patients with CKD [5]. The accumulation of Ca deposits in coronary vessels involves numerous mechanisms related to disturbances in mineral metabolism [27]. In the current study, we examined vascular calcification in patients with CKD using spiral CT and the Agatston scoring method. Our results showed that the CAC in this population was positively correlated with the serum levels of CRP, PTH, N-MID, P1NP, and β-CTx, but not Ca or P level. No significant difference was observed in the CAC scores of patients with CKD at different stages or receiving different treatments. Hospitalization analysis showed that patients with CAC scores of >400 (indicating a high risk of cardiovascular events) had a significantly higher risk of all-cause and cardiovascular hospitalizations than those with CAC scores of ≤400.

**Fig. 2** CAC scores in CKD patients receiving different treatments (CKD patients were categorized into five groups according to their eGFR: CKD stage 3, CKD stage 4, CKD stage 5 (without dialysis), CKD stage 5 (hemodialysis), and CKD stage 5 (peritoneal dialysis). Box plots were generated to demonstrate the overall distribution of CAC scores in each group.)

**Fig. 3** Survival curves for all-cause hospitalization of CKD Patient (CKD patients were categorized into different groups according to the CAC score (0, no risk of cardiovascular events or mortality; 1–100, low risk; 101–400, intermediate risk; >400, high risk). The survival curves for all-cause hospitalization of patients at each group were generated by the Kaplan-Meier method.)
Previous data showed that glomerulonephritis is the leading cause of CKD in China, followed by diabetic kidney disease, which is consistent with our results showing that chronic glomerulonephritis (39.0%) and diabetic nephropathy (28.1%) accounted for approximately 70% of all cases. The KDIGO workgroup recommended CKD-MBD, which encompasses systemic disorders of mineral and bone metabolism due to CKD, including altered levels of Ca, P, and PTH; disturbed bone modeling; and calcification in arteries and soft tissues [28]. Patients with CKD undergoing dialysis often demonstrate CKD-MBD-related symptoms, such as bone abnormalities and arterial calcification, making them high-risk for cardiovascular events and high morbidity and mortality rates [29]. In our study, the prevalence of CAC was 58.22% in the studied population, and 56 (38.36%) of the patients had CAC scores of >400, which was consistent with the data published in a recent meta-analysis showing that the overall prevalence of vascular calcification among patients with CKD was 60% (95% confidence interval: 53–68%) [30]. According to the Clinical Practice Guidelines for CKD-MBD, the serum levels of Ca, P, and PTH in CKD stages 3–5 are recommended to be maintained at a range of 2.1–2.5 mmol/L, 0.87–1.45 mmol/L, and 150–300 pg/ml, respectively. Here, we report that only 62.65%, 55.42%, and 21.69% of the patients showed normal serum levels of Ca, P, and PTH, respectively, indicating that better management of CKD-MBD is needed for patients with CKD.

Vascular calcification is a chronic and complex pathological process that involves multiple factors. We found no significant correlation between CAC score and FBG or LV ejection fraction, which was measured only once for all patients. Inflammation plays an important role in the development of vascular calcification and is positively correlated with aortic lesions in patients with CKD [31]. CRP is an inflammatory biomarker associated with arterial calcification and atherosclerosis and has been considered an independent risk factor for cardiovascular events [32, 33]. Here, we report a significant and positive correlation between CRP levels and CAC scores in patients with CKD.

Hyperphosphatemia and hypercalcemia are key factors that contribute to the initiation and progression of arterial calcification in patients with CKD [34]. Previous evidence revealed that serum Ca–P product is an
independent risk factor for vascular calcification in patients with CKD undergoing hemodialysis [35]. In this study, we found no significant correlation between CAC score and serum Ca or P. As these minerals are also affected by diet, nutritional status, or medications, a single measurement may not necessarily reflect the whole-body Ca and P.

An increase in serum PTH level has been reported to stimulate the release of Ca and P from bones, resulting in mineral metabolic disorders and vascular calcification in patients with CKD [36]. Consistently, our analysis showed a significant positive correlation between CAC score and PTH level. Patients with CKD often present with vitamin D deficiency and low levels of 25(OH)D, the predominant circulating form of vitamin D. A decrease in 25(OH)D level leads to reduced intestinal Ca absorption, decreased total Ca level, and elevated PTH level in the blood [37]. A study of 289 hemodialysis patients showed

---

**Table 3** Univariate and Multivariate predictor analyses of Rehospitalization

|                     | Univariate analysis | Multivariate analysis |
|---------------------|---------------------|-----------------------|
|                     | HR(95%CI)           | P                     |
|                     | HR(95%CI)           | P                     |
| Age                 | 1.02(1.01,1.03)     | 0.001                 |
| ALB                 | 0.96(0.92,0.99)     | 0.021                 |
|                    | 0.947(0.909,0.987)  | 0.009                 |
| UC                  | 0.999(0.997,1.00)   | 0.100                 |
| 25[OH]D             | 0.978(0.960,0.997)  | 0.021                 |
| CACstage*           | 2.31(1.52,3.52)     | 0.000                 |
|                     | 2.408(1.580,3.670)  | 0.000                 |

*25[OH]D:25 hydroxyl-vitamin D. (CGN; DN; HTN; β-CTx; N-MID; P1NP; LA; RV; EF; CVD; Sex; CACstage; primary renal disease; CKD stage; RRT; WBC, RGB; PT; CRP; ALP; GLU; Urea; Scr; Ca; P; Ca*P; TC; TG; HDL; LDL; AO) P > 0.1

**Table 4** Univariate and Multivariate predictor analyses of death

|                     | Univariate analysis | Multivariate analysis |
|---------------------|---------------------|-----------------------|
|                     | HR(95%CI)           | P                     |
|                     | HR(95%CI)           | P                     |
| Age                 | 1.10(1.04,1.17)     | 0.002                 |
| CVD*                | 4.53(1.17,17.51)    | 0.029                 |
| WBC                 | 1.35(1.13,1.63)     | 0.001                 |
| ALB                 | 0.89(0.80,0.997)    | 0.044                 |
| GLU                 | 1.13(0.98,1.29)     | 0.092                 |
| Urea                | 0.87(0.77,0.97)     | 0.013                 |
| Scr                 | 0.97(0.994,1.00)    | 0.024                 |
| UC                  | 0.995(0.99,1.00)    | 0.070                 |
| P                   | 0.25(0.07,0.91)     | 0.036                 |
| Ca*P                | 0.62(0.37,1.05)     | 0.075                 |

*CGN; DN; HD; PD; IPHT; β-CTx; N-MID; 25[OH]D; P1NP; LA; RV; EF; CVD; Sex; CACstage; CVD stage; RRT; Sex; RBC; HGB; PT; CRP; Ca; TC; TG; HDL; LDL; AO; EF; ALP) P > 0.1

---

**Fig. 5** Kaplan-Meier survival curves of CKD patients with different CAC scores (CKD patients were categorized into different groups according to the CAC score (0, no risk of cardiovascular events or mortality; 1–100, low risk; 101–400, intermediate risk; > 400, high risk). The Kaplan-Meier survival curves were generated using death as the endpoint of interest.)
that low 25(OH)D levels are inversely related to vascular calcification, but the statistical significance was lost after correcting for confounding factors [38]. In our pooled population, no significant correlation was observed between CAC score and 25(OH)D level. As some patients were administered bioactive vitamin D (calcitriol) during the study, the 25(OH)D level could have been altered, thereby reducing the risk of vascular calcification.

A relationship between vascular calcification and low bone turnover has been reported in hemodialysis patients [39]. In addition, the co-incidence of arterial calcification and osteoporosis implies that the correction of the imbalance in bone turnover may protect patients with CKD against vascular calcification [40]. In the current study, we analyzed bone metabolism parameters, including P1NP, β-CTx, and N-MID, to determine the correlations between CAC score and osteogenic activity, bone degradation, and bone turnover ratio. The results showed that CAC was positively correlated with P1NP, β-CTx, and N-MID levels in patients with CKD, suggesting the clinical value of bone turnover markers for predicting vascular calcification in these patients. Further hospitalization and survival analysis showed that patients with CAC scores of >400 had a significantly higher risk of all-cause and cardiovascular hospitalizations than patients with scores of ≤400. Despite differences in the survival curves of patients with CKD with different CAC scores, no statistical significance was observed, possibly because of the short duration of observation and the small sample size. Future investigations with a multi-center, prospective design, and larger sample size with non-hospitalized patients with CKD are warranted to validate the results of the current study and further explore the mechanisms of vascular calcification in CKD.

**Conclusion**

The main cause of CKD was glomerulonephritis, followed by diabetic kidney disease. The CAC score was positively correlated with markers of inflammation and bone metabolism. Patients with CKD with CAC scores of >400 showed a higher risk of all-cause and cardiovascular hospitalizations than those with low CAC scores. Therefore, a balanced bone metabolism is essential for the maintenance of cardiovascular health in patients with CKD.

**Acknowledgements**

The material included in this manuscript is original and it has been neither published elsewhere nor submitted for publication simultaneously. All authors of the manuscript have read and agreed to its content and are accountable for all aspects of the accuracy and integrity of the manuscript in accordance with ICMJE criteria.

**Author Contributions**

All authors have fulfilled the standard criteria for authorship. XXD and QH designed research collected patient data, WZ and YML analyzed data and performed statistical analysis, JH and XXD wrote the manuscript. All the authors read and approved the final manuscript.

**Funding**

The current research received no financial support.

**Data Availability**

The data that support the findings of this study are not publicly available due to their containing information that could compromise the privacy of research participants. But are available from the corresponding author on reasonable request; Dr Yueming Liu (lyuman136@126.com).

**Declarations**

Ethics approval and consent to participate

All participants gave their written informed consent to participate. The study was carried out in accordance with the Declaration of Helsinki and approved by the Medical ethics committee of zhejiang provincial people’s hospital Medical ethics committee of zhejiang provincial people’s hospital (Approval No. Zhejiang Medical Ethics Review 2022 OtherNo. (162)).

Consent for publication

Not applicable.

Conflict of interest

All authors had no known competing financial interest or personal relationship that could have appeared to influence the work reported in this paper. No tables or Figures are taken from other study.

**Funding**

The current research received no financial support.

**References**

1. Global regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England). 2020 Feb 29;395(10225):709–33.
2. Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet (London, England). 2012 Mar 3;379(9818):815 – 22.
3. Yuan J, Zou XR, Han SP, Cheng H, Wang L, Wang JW, et al. Prevalence and risk factors for cardiovascular disease among chronic kidney disease patients: results from the Chinese cohort study of chronic kidney disease (C-STRIDE). BMC Nephrol. 2017 Jan 14;18(1):23.
4. Karwowski W, Naumnik B, Szczepański M, Myśliwiec M. The mechanism of vascular calcification – a systematic review. Med Sci Monit. Int Med J experimental Clin Res. 2018;18(1):RA1–11.

5. Pailt S, Kendrick J. Vascular calcification in chronic kidney disease: role of disordered mineral metabolism. Curr Pharm Design. 2014;20(3):5829–33.

6. Benz K, Hilgers KF, Daniel C, Amann K. Vascular Calcification in Chronic Kidney Disease: The Role of inflammation. Int. J Nephrol. 2018;2018:103039.

7. Shanahan CM. Mechanisms of vascular calcification in CKD-evidence for premature ageing? Nat Rev Nephrol. 2013 Nov;9(11):661–70.

8. Shroff R, Long DA, Shanahan C. Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol. 2013 Feb;24(2):179–89.

9. Shanahan C, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Kidney Int. 2011 Dec;80(12):1250–7.

10. Yamada S, Taniguchi M, Tokumoto M, Toyonaga J, Fujisaki K, Suehiro T, et al. The antioxidant tempol ameliorates arterial medial calcification in uremic rats: important role of oxidative stress in the pathogenesis of vascular calcification in chronic kidney disease. J Bone Miner Res. 2012 Feb;27(2):474–85.

11. McCabe KM, Booth SL, Fu X, Shobeiri N, Pang JJ, Adams MA, et al. Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. Kidney Int. 2013 May;83(5):835–44.

12. Kaebers N, Goetshas W, Weis D, Schugens L, Hellmann B, Floege J, et al. Magnesium but not nicotinamide prevents vascular calcification in experimental uremia. Nephrol Dial Transplant. 2020 Jan;35(1):65–73.

13. Xu Z, Ji G, Shen J, Wang X, Zhou J, Li L. SOK9 and myocardin counteract each other in regulating vascular smooth muscle cell differentiation. Biochem Biophys Res Commun. 2012 Jun 1;422(2):285 – 90.

14. Cai T, Sun D, Duan Y, Wen P, Dai C, Yang J, et al. WNT/beta-catenin signaling promotes VSMCs to osteogenic transdifferentiation and calcification through directly modulating Runx2 gene expression. Exp Cell Res. 2016 Jul 15;345(2):206–17.

15. Voekel J, Luong TT, Tuffaha R, Musculus K, Auer T, Lian X, et al. SGRK1 induces vascular smooth muscle cell calcification through NF-kappaB signaling. J Clin Invest. 2018 Jul 2;128(7):3024–40.

16. Voekel J, Lang F, Eckardt KU, Amann K, Kuro OM, Pasch A, et al. Signaling pathways involved in vascular smooth muscle cell calcification during hyperphosphatemia. Cell Mol Life Sci. 2019 Jun;76(11):2077–91.

17. Askar AM. Hyperphosphatemia: The hidden killer in chronic kidney disease. Saudi Med J. 2015 Jan;36(1):13–9.

18. Ye C, Xu M, Wang S, Jiang S, Chen X, Zhou X, et al. Decreased Bone Mineral Density Is an Independent Predictor for the Development of Atherosclerosis: A Systematic Review and Meta-Analysis. PLoS ONE. 2016;11(5):e0154740.

19. Mazzaferrro S, Pasquali M, Taggi F, Baldinelli M, Conte C, Muci ML, et al. Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation. Clin J Am Soc Nephrol. 2009 Mar;4(3):685–90.

20. Faille D, Liu S, Yang ZWang. Z. Control Design Model for a Solar Tower Plant. Energy Procedia. 2014;49:2080–89.

21. Alffeni C, Forzenigo L, Tripodi F, Meneghini M, Regalia A, Cresseri D, et al. Long-term evaluation of coronary artery calcification in kidney transplanted patients: a follow up of 5 years. Sci Rep. 2019 May 3;9(1):16869.

22. Wilkeason TJ, Rahman MO, Gangi AS, Voss M, Ingram AJ, Ranganath N, et al. Coronary artery calcification, cardiovascular events, and death: a prospective cohort study of incident patients on hemodialysis. Can J Kidney Health Dis. 2015;2:29.

23. Yousef G, Kalia N, Darabian S, Budoff MJ. Coronary calcium: new insights, recent data, and clinical role. Curr Cardiol Rep. 2013 Jan;15(1):325.

24. Reeves PO, Andrade J, Monção H. Coronary artery calcium score: current status. Radiologia brasileira. 2017 May-Jun;50(3):182–89.

25. Lu J, Neal B, Ehteshami P, Nisnamiya T, Wobdward M, Rodgers A, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Med. 2012;9(8):e1001293.

26. Liu ZH, Li G, Zhang L, Chen J, Chen X, Zhao J, et al. Executive Summary: Clinical Practice Guideline of Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD) in China. Kidney diseases (Basel, Switzerland). 2019 Oct;5(4):197–203.

27. Viegas C, Araújo N, Marreiros C, Simes D. The interplay between mineral metabolism, vascular calcification and inflammation in Chronic Kidney Disease (CKD): challenging old concepts with new facts. Aging. 2019 Jun 26;11(12):4274–99.

28. Moomr RN, Moe SM. CKD-mineral and bone disorder: core curriculum 2011. Am J Kidney Dis. 2011 Dec;58(6):1022–36.

29. Waziri E, Duarte R, Naicker S. Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Current Perspectives. Int J Nephrol renovascular disease. 2019;12:263–76.

30. Wang XR, Zhang JJ, Xu XY, Wu YG. Prevalence of coronary artery calcification and its association with mortality, cardiovascular events in patients with chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2019 Nov;41(11):244–56.

31. Yamada S, Tokumoto M, Tatsurumo N, Taniguchi M, Noguchi H, Nakano T, et al. Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia. American journal of physiology Renal physiology. 2014 Jun 15;306(12):F1418-28.

32. Kralinski A, Drozdz M, Pasowicz M, Chimel G, Michalek M, Szumlak D, et al. Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrol Dial Transplant. 2007 Feb;22(2):515–21.

33. Kui Weber CJ, Duchateau-Nguyen G, Soler C, Schell-Steaven A, Hermosilla R, Nogecke E, et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease-Stages 3 and 4. Clin Kidney J. 2014 Apr;7(2):167–73.

34. Shaman AK, Kowalski SR. Hyperphosphatemia Management in Patients with Chronic Kidney Disease. Saudi pharmaceutical journal: SPJ : the official publication of the Saudi Pharmaceutical Society. 2016 Jul;24(4):494–505.

35. Paloin NJ, Giachelli CM. A current understanding of vascular calcification in CKD. American journal of physiology Renal physiology. 2014 Oct 15;307(8):F891–900.

36. Byron CR, Chen Y. Molecular Mechanisms of Vascular Calcification in Chronic Kidney Disease: The Link between Bone and the Vasculature. Current osteoporosis reports. 2015 Aug;13(4):206–15.

37. Bosworth C, de Boer IH. Impaired vitamin D metabolism in CKD. Semin Nephrol. 2013 Mar;33(2):158–68.

38. Chang JH, Chen Y. Molecular Mechanisms of Vascular Calcification in Chronic Kidney Disease: Challenging Old Concepts with New Facts. Aging. 2019 Jun;11(12):4274–99.

39. Cannata-Andia JB, Roman-Garcia P, Hruska K. The connections between renal bone disease and cardiovascular disease. Clin J Am Soc Nephrol. 2013 Mar;8(3):458–69.

40. Lu KC, Wu CC, Yen JF, Liu WC. Vascular calcification and renal bone disorders. TheScientificWorldJournal. 2014;2014:637065.